dolutegravir/abacavir/lamivudine — Competitive Intelligence Brief

dolutegravir/abacavir/lamivudine (dolutegravir/abacavir/lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTIs). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (INSTI + NRTIs) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

dolutegravir/abacavir/lamivudine (dolutegravir/abacavir/lamivudine) — University College Dublin. This combination inhibits HIV reverse transcriptase and integrase to block viral replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dolutegravir/abacavir/lamivudine TARGET	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
Regimen：BIC+FTC+TAF	Regimen：BIC+FTC+TAF	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Bictegravir, emtricitabine, and tenofovir alafenamide	Bictegravir, emtricitabine, and tenofovir alafenamide	CAN Community Health	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTIs) class)

1. University College Dublin · 1 drug in this class
2. ViiV Healthcare · 1 drug in this class